GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Journal of the American College of Cardiology · 2023-08 · 82 (6) · 517-525
DOI: 10.1016/j.jacc.2023.05.048 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the American College of Cardiology, 2023-08. Verfasst von João Sérgio Neves und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Departmen…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear. OBJECTIVES: The aim of this study was to evaluate the effects of GLP-1 RAs on cardiovascular outcomes in patients with T2D treated with or without SGLT2 inhibitors. METHODS: Post hoc analysis of Harmony Outcomes (Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease) evaluating the effect of albiglutide in T2D with cardiovascular disease by background SGLT2 inhibitor use. Additionally, a trial-level meta-analysis of Harmony Outcomes and AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes), which evaluated T2D with cardiovascular or renal disease, was performed, combining the treatment effect estimates according to SGLT2 inhibitor use. RESULTS: Of the 9,462 participants in Harmony Outcomes, 575 (6.1%) were treated with SGLT2 inhibitors at baseline. The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). The effect of albiglutide on secondary outcomes and adverse events was not modified by SGLT2 inhibitors. A meta-analysis of Harmony Outcomes and AMPLITUDE-O included 13,538 patients, of whom 1,193 (8.8%) used SGLT2 inhibitors. Compared to placebo, GLP1-RAs reduced major adverse cardiovascular events without effect modification by SGLT2 inhibitor use (HR: 0.77; 95% CI: 0.68-0.87 without SGLT2 inhibitors; and HR: 0.78; 95% CI: 0.49-1.24 with SGLT2 inhibitors) (P for interaction = 0.95) and reduced heart failure hospitalization (HR: 0.72; 95% CI: 0.55-0.92 vs HR: 0.34; 95% CI: 0.12-0.96) (P for interaction = 0.18). CONCLUSIONS: In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Univers…
- Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Department of Internal Medicine, Centro Hospitalar Universitário de São João, P…
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
- Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculty of Medicine of the University of Porto, Porto, Portugal; Instituto de Investigação e Inovação e…
- Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Department of Cardiothoracic Surgery, Centro Hospitalar Universitário São João,…
Zitieren
APA
Neves, J. S., Borges-Canha, M., Vasques-Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D., Leite-Moreira, A., Hernandez, A. F., Del Prato, S., McMurray, J. J. V., & Ferreira, J. P. (2023). GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 82(6), 517-525. https://doi.org/10.1016/j.jacc.2023.05.048
Vancouver
Neves JS, Borges-Canha M, Vasques-Nóvoa F, Green JB, Leiter LA, Granger CB, et al. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. Journal of the American College of Cardiology. 2023;82(6):517-525. doi:10.1016/j.jacc.2023.05.048
BibTeX
@article{Neves2023,
author = {Neves, João Sérgio and Borges-Canha, Marta and Vasques-Nóvoa, Francisco and Green, Jennifer B and Leiter, Lawrence A and Granger, Christopher B and Carvalho, Davide and Leite-Moreira, Adelino and Hernandez, Adrian F and Del Prato, Stefano and McMurray, John J V and Ferreira, João Pedro},
title = {GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes},
journal = {Journal of the American College of Cardiology},
year = {2023},
volume = {82},
number = {6},
pages = {517--525},
doi = {10.1016/j.jacc.2023.05.048}
}
EUVIMED